Head-To-Head Review: BioAtla (NASDAQ:BCAB) versus Genfit (NASDAQ:GNFT)

BioAtla (NASDAQ:BCAB) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares BioAtla and Genfit’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	-187.30%	-96.33%
Genfit	N/A	N/A	N/A

Valuation and Earnings

This table compares BioAtla and Genfit”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$250,000.00	292.03	-$123.46 million	($1.70)	-0.89
Genfit	$76.06 million	2.94	-$31.27 million	N/A	N/A

Genfit has higher revenue and earnings than BioAtla.

Insider and Institutional Ownership

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 2.2% of Genfit shares are owned by institutional investors. 11.5% of BioAtla shares are owned by insiders. Comparatively, 4.2% of Genfit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

BioAtla has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioAtla and Genfit, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	0	1	1	0	2.50
Genfit	0	0	1	0	3.00

BioAtla presently has a consensus target price of $6.00, suggesting a potential upside of 297.35%. Genfit has a consensus target price of $13.00, suggesting a potential upside of 190.83%. Given BioAtla’s higher possible upside, analysts plainly believe BioAtla is more favorable than Genfit.

Summary

Genfit beats BioAtla on 6 of the 10 factors compared between the two stocks.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.